Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
Key Inclusion Criteria:
Key Exclusion Criteria:
Waldenström macroglobulinemia
For newly diagnosed multiple myeloma: multiple myeloma of IgM subtype
For relapsed disease:
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
Plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)
Myelodysplastic syndrome
Amyloidosis
Prior treatment with carfilzomib or oprozomib
Bakersfield, California, United States
Washington D.C., District of Columbia, United States
Hackensack, New Jersey, United States
Charleston, South Carolina, United States